Figure 1: Kaplan-meier Estimation Of Cumulative Proportion Of Patients With Relapse (mdd Study 5) (Duloxetine Fig1)
Duloxetine Hydrochloride
Product Images NDC 50436-0018
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Duloxetine Hydrochloride (NDC 50436-0018). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Unit Dose Services, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Figure-2 (Duloxetine Fig2)
This is a graph displaying the proportion of patients experiencing relapse over time for a particular treatment compared to a placebo. The treatment is not specified, but it is being compared to the drug duloxetine. The vertical axis shows the proportion of patients experiencing relapse and the horizontal axis is the time (in days) from randomization. The graph shows that the treatment is more effective than the placebo, as fewer patients on the treatment experience relapse over time.*
Figure 3: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-1)
This is a graph displaying the percentage of patients who achieved different levels of pain relief after taking Duloxetine 60mg B ID and QD, and placebo. The graph is labeled "Figure 3" and titled "Percentage of Patients Achieving Various Levels of Pain Relief as Measured by 24-Hour Average Pain Severity - DPNP-1". There are different data points on the graph ranging from 0 to 40. There is no additional information available for context.*
Figure 4: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity (DPNP-2)
This is a graph labeled "Figure 4" which shows the percentage of patients who achieved various levels of pain relief for diabetic peripheral neuropathic pain (DPNP), as measured by 24-hour average pain severity. The x-axis shows the percentage improvement in pain from baseline, while the y-axis shows the number of patients. The graph is specifically for patients who were given Duloxetine 60mg and it is not possible to determine the full context of the study from this single graph.*
Figure 7: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-1 (Duloxetine Fig5)
Figure 8: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Clbp-3 (Duloxetine Fig6)
The text is describing a chart showing the percentage of patients who have achieved various levels of pain relief after taking a certain medication. The medication is a combination of Placebo and Duloxetine taken at 60 mg per day. The chart represents improvement in pain in percentage and is plotted against the percent improvement in pain from a baseline. Figure 8 displays the percentage of patients achieving various levels of pain relief as measured by a 24-hour average pain severity.*
Figure 9: Percentage Of Patients Achieving Various Levels Of Pain Relief As Measured By 24-hour Average Pain Severity – Oa-1 (Duloxetine Fig7)
This appears to be a graph or figure related to a clinical trial or study evaluating the effects of a medication called Duloxetine in treating pain. The graph measures the percentage of patients experiencing pain relief at various levels, with one group taking Duloxetine and the other taking a placebo. The dosing of Duloxetine is specified as 60mg/420 mg once daily. However, without additional context or information, it is difficult to provide a complete description of the study or its results.*
Structure (Duloxetine Str)
Label Image (Lbl504360018)
Duloxetine hydrochloride is a medication that comes in delayed-release capsules with strengths of 30mg and 60mg, labeled with NDC number 50436-0018-2. The manufacturer, Citron Pharma LLC, is based in East Brunswick NJ 08816. Other information provided in the text is not available due to missing or unclear characters.*
Label Image (Lbl504360019)
This text provides information about a medication named "Duloxetine Hydrochloride" in a "60 MG / 30 CAP" delayed-release capsule form. The medication is manufactured by Citron Pharma LLC and the NDC code for the medicine is 50436-0019-1. Apart from this, few manufacturing details have also been provided like MFGNDC (57237-019-30) and MFG LOT (XXKKKKX). The LOT (XXHKK) and EXP (XXXKK) details also available.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
